2009 Competition Pharmaceutical manufacturing 
pharmaphorum
JANUARY 24, 2023
Over the last 25 years, the headcount in the medicines manufacturing sector has fallen by 7,000 and since 2009 production volumes have fallen by nearly a third (29%), suggesting “faltering attractiveness” of the UK for manufacturing. ” Image from the Association of the British Pharmaceutical Industry (ABPI).
pharmaphorum
DECEMBER 28, 2022
M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. In 2018, over 60% of all new molecular entities came from smaller biopharma firms, compared with just over 30% in 2009.
Expert insights. Personalized for you.
107 
Let's personalize your content